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ABSTRACT
Free fatty acids (FFA) physiologically regulate GH release via a
negative feedback. The aim of this study was to examine whether such
feedback is preserved in acromegaly, a condition in which alterations
in other regulatory mechanisms of GH release occur. Eight acrome-
galic patients (group 1: five women and three men, 43.0 6 4.2 yr old,
mean 6 SE) received per os on two different days, at a 3 day-interval,
in a random order, placebo or 250 mg of acipimox, an inhibitor of
lipolysis analogous to nicotinic acid, at 0700 and 1100 h. In both tests
GHRH (1–29 NH2), 50 mg, was administered iv at 1300 h. Blood
samples for GH, FFA, immunoreactive insulin (IRI), and glucose were
taken from 0900 to 1500 h, and the time period considered for sta-
tistical analysis was 1200–1500 h, representative of steady-state con-
dition for FFA, IRI, and glucose. Mean plasma FFA levels (1200–1500
h) were significantly lower after acipimox than after placebo (0.05 6
0.01 vs. 0.17 6 0.01 g/L, P , 0.01). In contrast, both mean basal GH
levels (1200–1300 h) and the mean GH response to GHRH (GH D area,
1300–1500 h) were significantly higher after acipimox than after
placebo (12.0 6 1.9 vs. 7.8 6 1.2 mg/L, P , 0.01; 2937 6 959 vs. 1154 6
432 mg/Lz120 min, P , 0.01). The increase in both basal GH levels and
GH D area occurred in all eight patients. Acipimox also reduced mean
serum IRI (83 6 12 vs. 112 6 14 pmol/L) and blood glucose (5.1 6 0.1
vs. 5.7 6 0.1 mmol/L) levels, as compared with placebo (P , 0.03 or
less). Eight acromegalic patients (group 2: six women and two men,
46.6 6 5.7 yr old) underwent a constant iv 10% lipid infusion (150
mL/h), started at 0900 h and continued until 1500 h. Mean plasma
FFA levels (1200–1500 h) were significantly higher during lipid in-
fusion than after placebo (0.27 6 0.01 vs. 0.16 6 0.01 g/L, P , 0.02);
in contrast, mean basal GH levels (1200–1300 h) were reduced by
lipid infusion, as compared with placebo (9.9 6 3.1 vs. 16.6 6 4.4 mg/L,
P , 0.01), and the same occurred for the GH D area after GHRH
(2498 6 1643 vs. 4512 6 1988 mg/Lz120 min, P , 0.01). Serum IRI and
blood glucose levels were similar after placebo and during lipid
infusion.
These data indicate that, in acromegaly, the acute reduction of
circulating FFA levels results in increased GH release, whereas the
increase in circulating FFA levels is accompanied by a reduced GH
release. Taken together, these findings suggest that, in acromegaly,
the control of FFA on GH release is preserved. (J Clin Endocrinol
Metab 84: 1234–1238, 1999)
GH SECRETION is regulated by two specific hypotha-lamic neurohormones, the stimulatory GHRH and the
inhibitory SRIF (1). The release of these neurohormones, in
turn, is modulated by a large cohort of neurotransmitters,
peptides, hormones, and metabolic variables.
Acromegaly is a pathological condition characterized by
elevated circulating GH levels, which are usually detect-
able at all times and fluctuate widely throughout the day
(2, 3). High GH levels are attributable to GH hypersecre-
tion that is caused, with few exceptions (4 – 6), by a pitu-
itary adenoma, and do not depend on an alteration in the
processes of GH distribution or disappearance (7). Several
abnormalities have been reported in the mechanisms gov-
erning GH secretion in acromegalic patients. In vivo GH
hypersecretion occurs in spite of high circulating insulin-
like growth factor I (IGF-I) levels, indicating disruption of
the negative IGF-I feedback on GH release (8). Further-
more, the GH response to the normally suppressive effect
of hyperglycemia is variable, because GH levels may rise,
be partially suppressed, or not change after an oral glucose
load (9, 10). In addition, there is often paradoxical respon-
siveness to l-dopa (11) and dopamine agonists (12, 13),
and to stimuli that do not affect GH release in normal
subjects [TRH, GnRH, CRH, vasoactive intestinal peptide
(VIP), peptide histidine methionine)] (14 –18). In the ma-
jority of acromegalic patients, however, circulating GH
levels decrease after administration of SRIH and its ana-
logs (19 –21). This finding supports the hypothesis that, in
acromegaly, GH secretion is not completely autonomous
but is under some degree of hypothalamic regulation. Data
obtained in vitro in static incubations (22, 23) and via
perifusion systems (24) also indicate that most GH-secret-
ing pituitary adenomas maintain, at least qualitatively, a
normal sensitivity to the hypothalamic regulatory hor-
mones GHRH and SRIH and also to the peripherally gen-
erated IGF-I and insulin (25).
In this complex and variable pathophysiologic circum-
stance, we are unaware of any information about the effects
of free fatty acids (FFA). FFA exert a negative feedback on
GH release under physiological conditions (26–31). To in-
vestigate whether the FFA-negative feedback on GH release
persists in acromegaly, we designed a placebo-controlled
study in which GH release was analyzed after: 1) acute re-
duction of circulating FFA levels by pharmacologic blockade
of lipolysis; and 2) acute increase of circulating FFA levels
induced by iv lipid infusion.
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Subjects and Methods
Subjects and experimental procedures
The protocol for the study was approved by the local ethics
committee. Fifteen consecutive acromegalic patients, hospitalized at
Ospedale San Raffaele (10 women and 5 men), were admitted to the
study after giving written informed consent. Subjects characteristics are
shown in Table 1. Diagnosis of active acromegaly was based on the
clinical picture, failure of GH levels to suppress under 2 mg/L after an
oral glucose load, and elevated plasma IGF-I levels. All acromegalic
patients had a pituitary adenoma, by magnetic resonance imaging, con-
firmed at surgery.
Following an experimental protocol, previously designed by our
group to investigate the interplay GH/FFA in normal subjects (27, 28),
the first eight acromegalic subjects (group 1 of Table 1) received (per os,
on two different days, at a 3 day-interval, and in a random order) placebo
or 250 mg acipimox (Olbetam, Pharmacia & Upjohn, Inc., Milan, Italy)
at 0700 h and at 1100 h. Acipimox is an inhibitor of lipolysis analogous
to nicotinic acid that is known to act only on the adipose tissue (32, 33).
In both tests, GHRH (1–29 NH2), 50 mg iv, was administered at 1300 h.
Patients no. 9–15 (group 2 of Table 1) underwent (on two different
days, at a 3-day interval, and in random order) a 0.9% NaCl infusion or
a constant lipid infusion (Intralipid 10%) (31) at the rate of 150 mL/h,
started at 0900 h and continued until 1500 h. GHRH (50 mg, iv) was
administered at 1300 h. Patient no. 7 underwent both tests, with acipi-
mox or lipid infusion, and was therefore included in both groups.
In each test, blood samples for evaluation of serum GH levels were
taken every 10 min, from 0900 h to 1300 h (time of GHRH injection) and
15, 30, 45, 60, 90, and 120 min after, via an indwelling catheter inserted
into a forearm vein at least half an hour before the beginning of the
sampling period. Blood samples for evaluation of plasma FFA, serum
insulin [immunoreactive insulin (IRI)], and blood glucose levels were
taken every 30 min throughout each study.
Patients no. 1, 4–8, and 10–15 also underwent a TRH test (200 mg, iv),
with blood samples for GH taken at 0, 15, 30, 45, 60, 90, and 120 min.
On the day of each test, all subjects were fasted overnight and remained
recumbent throughout the test.
Assays
Plasma FFA levels were measured by a spectrophotometric method
adapted to Cobas-Fara 2 (Roche, Basel, Switzerland) using kits supplied
by Italfarmaco (Milano, Italy). Intra- and interassay coefficients of vari-
ations (CVs) were 2.3 and 3.1%, respectively. Serum IRI levels were
measured by RIA using kits supplied by INCSTAR Corp. (Stillwater,
MN). The minimum sensitivity of the assay was 13 pmol/L, and intra-
and interassay CVs were 3.9 and 8.9%, respectively. Serum GH levels
were measured by RIA using kits supplied by Farmos Diagnostic
(Turku, Finland). The minimum sensitivity of the assay was 0.2 mg/L,
and the median intra- and interassay CVs for GH concentrations, rang-
ing from 0.2–50 mg/L, were less than 9 and 10%, respectively. Blood
glucose levels were measured by a glucose oxidase method (Glucose
Analyzer II, Beckman Coulter, Inc. Instruments, Fullerton, CA).
Calculations and statistical analysis
For all the variables, statistical analysis was performed for the interval
1200–1500 h. From 1200 h, in fact, steady-state conditions for plasma
FFA, serum IRI, and blood glucose levels were evident in all tests and
were maintained until 1500 h. Mean basal GH levels therefore represent
the mean of seven samples between 1200 and 1300 h. The integrated GH
response to GHRH (GH D area) was calculated, by the trapezoidal
method, over the 2 h after GHRH injection (1300–1500 h). Because of the
nonnormal distribution of the data (assessed by the Kolmogorov-Smir-
nov test), the comparisons of both basal GH levels and the GH D areas
after placebo/acipimox (group 1) and placebo/lipid infusion (group 2)
were performed by the nonparametric Wilcoxon signed-rank test. Com-
parisons of mean plasma FFA, blood glucose, and serum IRI levels
(mean of seven samples between 1200 h and 1500 h) were performed by
the Student’s t test for paired data. The Pearson product-moment cor-
relation coefficient was used to evaluate the degree of correlation be-
tween all parameters reported in Results.
Results
Figure 1 represents plasma FFA and serum GH levels
between 1200 h and 1500 h in patients of group 1, receiving
placebo or acipimox at 0700 and 1100 h. In all eight patients,
mean plasma FFA levels were significantly lower after acipi-
mox than after placebo. The acute reduction of plasma FFA
levels induced by acipimox was accompanied by a significant
increase of both basal serum GH levels and of the GH re-
sponse to GHRH (GH D area). Numeric values and statistical
comparisons for all the variables are reported in the left panel
of Table 2. Acipimox administration, besides significantly
reducing plasma FFA levels and increasing GH levels, also
induced a significant decrease of mean serum IRI and blood
glucose levels.
In subjects of group 2, lipid infusion (started at 0900 h)
TABLE 1. Clinical details of acromegalic patients
Subjects Sex/age (yr) Weight (kg) BMI (kg/m2) Size of the tumor
Group 1
1 M/34 88 25.1 Microadenoma
2 M/48 107 33.4 Microadenoma
3 F/57 70 25.9 Microadenoma
4 M/28 95 26.3 Macroadenoma
5 F/39 72 30.0 Macroadenoma
6 F/40 68 25.1 Macroadenoma
7 F/63 83 27.6 Microadenoma
8 F/35 88 33.8 Microadenoma
mean 6 SE 43.0 6 4.2 83.8 6 4.7 28.4 6 1.2
Group 2
7 F/63 83 27.6 Microadenoma
9 F/32 70 28.0 Macroadenoma
10 F/64 60 24.0 Macroadenoma
11 F/65 73 29.2 Microadenoma
12 M/53 77 27.5 Microadenoma
13 F/37 64 22.8 Macroadenoma
14 F/26 67 24.8 Macroadenoma
15 M/33 99 33.0 Microadenoma
mean 6 SE 46.6 6 5.7 74.1 6 4.3 27.1 6 1.1
BMI, Body mass index.
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progressively increased circulating FFA levels, so that by
1200 h, a new steady-state for plasma FFA was reached, and
maintained until 1500 h (Fig. 2, upper panel). In all subjects
of group 2, the increase in plasma FFA levels was accom-
panied by a concomitant significant reduction of basal serum
GH levels, as well as of the GH D area (Fig. 2, lower panel).
Numeric values and statistical comparisons for all the vari-
ables are reported in the right panel of Table 2. Mean serum
IRI and blood glucose levels remained unaffected by lipid
infusion. To clarify the effect of acipimox administration and
of lipid infusion on GH levels in acromegaly, the GH profiles
of subject no. 7 (who underwent tests with placebo, acipimox,
and lipid infusion) are shown in Fig. 3.
Table 3 reports a qualitative comparison between the GH
response to GHRH after placebo or acipimox, and during
lipid infusion, and that to TRH after placebo (positive re-
sponse: GH D peak, i.e. GH increment above basal levels,
.50%). After placebo, patients of both groups showed a
variable response to TRH and GHRH. In addition to the
significant increase in GH D area after acipimox (Table 2), all
subjects of group 1 showed a qualitatively positive response
to GHRH (Table 3, upper panel). In all subjects of group 2, GH
D peak after GHRH was reduced by lipid infusion; however,
five of eight subjects, responsive after placebo, continued to
be responsive also at higher plasma FFA levels (Table 3, lower
panel).
In both groups of acromegalic patients, no correlations
were found between mean FFA levels, basal GH levels, and
the GH response to GHRH, after either placebo, acipimox
administration, or lipid infusion.
Discussion
Among the abnormalities in the control of GH secretion
that have been described in acromegaly, refractoriness to the
glucose inhibiting effect (9, 10) and the paradoxical respon-
siveness to several stimuli (11, 14–18) have been widely used
as tools for diagnosis and postoperative evaluation. We are
unaware of any data, however, regarding the persistence of
FFA-negative feedback on GH release in acromegaly.
The results of the present study indicate that, in acromeg-
aly, as in nonacromegalic subjects (26–31), the acute reduc-
tion of circulating FFA levels results in increased GH release,
whereas an increase in circulating FFA levels is accompanied
by a reduced GH release. Of note is that enhancement of GH
release after acipimox was evident in all patients, both qual-
itatively and quantitatively. On the other hand, lipid infusion
decreased GH release in all patients, but five of eight of them
continued to be responsive to GHRH (GH D peak . 50%).
This could reflect a higher sensitivity of the adenoma cells to
a decrease, rather than to an increase in circulating FFA
levels. In any case, taken together, our findings suggest that,
in acromegaly, GH-secreting adenomatous pituitary cells
maintain their sensitivity to the negative control exerted by
FFA.
These data are in agreement with previous reports indi-
cating that GH secretion is not completely autonomous in
acromegaly (19–25). Particularly, the normal (at least qual-
itatively) sensitivity to SRIH in most GH-secreting pituitary
adenomas (19, 20, 22–24) may explain, in part, the persistent
inhibitory effect of FFA on GH release in acromegaly, be-
cause experimental evidence suggests that FFA may trigger
SRIH release from the hypothalamus (34). Other explana-
tions include the persistence of the direct FFA inhibitory
effect on the GH-secreting adenoma cells. Experimental ev-
idence indicates that FFA may exert a nonselective blockade
of spontaneous, as well as of GHRH-, TRH-, and VIP-stim-
ulated GH release, directly at the pituitary (35–39). At this
level, the main target for the biological actions of FFA seems
to be the cellular membranes of the somatotrophs, via a
perturbation of the lipid bilayer and a disruption of the
lipid-lipid and lipid-protein interaction. Because plasma-
borne FFA molecules are not covalently linked in the plasma
membranes, but are included in the bilayer as wedges (40),
they may fluctuate. Therefore, a change in the gradient of
FFA from plasma toward cell membranes (as induced by
acipimox and lipid infusion in this study) is able to modify
the membrane FFA content (41) and to affect many biological
functions, including cell-to-substrate adhesion, surface re-
ceptor capping, and transmembrane signaling (42–45).
Relevant to our study are previous findings indicating that
caprylic acid and cis-unsaturated FFA are able to reduce
FIG. 1. Upper panel, Plasma FFA levels (1200–1500 h), after oral
placebo and acipimox administration (0700 and 1100 h), in eight
acromegalic subjects of group 1; lower panel, basal serum GH levels
and GH response to GHRH, after placebo and acipimox administra-
tion, in the same subjects.
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GHRH- and VIP-stimulated GH release of cultured pituitary
cells via a reduction, at least in part, of the adenylate cyclase
activity (36, 39). In fact, it is known that about 40% of GH-
secreting pituitary adenomas show a constitutive activation
of the adenylate cyclase-cAMP system, caused by a point
mutation in the a-subunit of the Gs protein linked to the
adenylate cyclase coupled with the GHRH receptor (46). In
our preliminary study, the mutation of the Gs protein has not
been evaluated in any of the acromegalic patients. Our find-
ing that, in all acromegalic patients examined, the GHRH-
stimulated GH release was increased (or even became evi-
dent when absent after placebo) after acipimox, and was
reduced by lipid infusion, needs therefore to be reconsidered
in relation to such a mutation. The finding that FFA could
persistently regulate GH release in response to GHRH, also
TABLE 2. Experimental parameters after placebo or acipimox (group 1) and after placebo and during lipid infusion (group 2)
Group 1 Group 2
Parameters
Treatment
P Parameters
Treatment
P
Placebo Acipimox Placebo Lipid infusion
Mean FFA levels (g/L) 0.17 6 0.01 0.05 6 0.01 ,0.01 Mean FFA levels (g/L) 0.16 6 0.01 0.27 6 0.01 ,0.02
Mean basal GH levels (mg/L) 7.8 6 1.2 12.0 6 1.9 ,0.01 Mean basal GH levels (mg/L) 16.6 6 4.4 9.9 6 3.1 ,0.01
GH D area (mg/Lz120 min) 1154 6 432 2937 6 959 ,0.01 GH D area (mg/Lz120 min) 4512 6 1988 2498 6 1643 ,0.01
Mean IRI levels (pmol/L) 112 6 14 83 6 12 ,0.03 Mean IRI levels (pmol/L) 105 6 18 126 6 19 ns
Mean glucose levels (mmol/L) 5.7 6 0.1 5.1 6 0.1 ,0.01 Mean glucose levels (mmol/L) 5.6 6 0.3 6.2 6 0.6 ns
ns, Not significant.
FIG. 2. Upper panel, Plasma FFA levels (1200–1500 h), after oral
placebo (0700 and 1100 h) and during iv 10% lipid infusion, in eight
acromegalic subjects of group 2; lower panel, basal serum GH levels
and GH response to GHRH, after placebo and during lipid infusion,
in the same subjects.
FIG. 3. Basal serum GH levels and GH response to GHRH in a single
representative acromegalic subject (no. 7) after oral placebo (E) and
acipimox (F) administration and during iv 10% lipid infusion ().
Acipimox enhanced, and lipid infusion reduced both basal and GHRH-
stimulated GH release, as compared with placebo.
TABLE 3. Qualitative analysis of the GH response to TRH and to
GHRH (GH D peak) after placebo and acipimox, and during lipid
infusion in acromegalic patients of groups 1 and 2
TRH (200 mg iv) GHRH (50 mg iv)
Group 1 Placebo Acipimox
1 2 1 1
2 NP 1 1
3 NP 1 1
4 1 1 1
5 2 1 1
6 1 2 1
7 1 1 1
8 1 1 1
Group 2 Placebo Lipid infusion
7 1 1 1
9 NP 1 2
10 1 1 1
11 2 2 2
12 1 1 1
13 2 2 2
14 1 1 1
15 1 1 1
NP, Not performed. 919, GH increment .50% above basal levels;
929, ,50% above basal levels.
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in the presence of the so-called gsp oncogene, could, in fact,
bring new insights regarding the intracellular mechanisms
involved in the FFA control of GH release. In this regard, it
could also be of interest to examine, in acromegalic patients,
the influence that FFA may exert on the GH release induced
by stimuli acting via pathways other than the adenylate
cyclase-cAMP system, such as TRH.
In conclusion, our preliminary data indicate that, in acro-
megaly, the acute reduction of circulating FFA levels results
in increased GH release, whereas the increase in circulating
FFA levels is accompanied by a reduced GH release. Taken
together, these findings indicate that, in acromegaly, the
control exerted by FFA on GH release is preserved. Further
studies are needed to investigate the mechanisms involved,
which may provide new insight about the pathophysiology
of GH release in acromegaly.
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